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Proteomic and functional analysis identifies galectin-1
as a novel regulatory component of the cytotoxic
granule machinery
Tiago Clemente1,2, Narcisio J Vieira1,2, Juan P Cerliani3, Colin Adrain4, Alexander Luthi5, Mariana R Dominguez6, Monica Yon1,2,
Fernanda C Barrence7, Thalita B Riul8, Richard D Cummings9, Telma M Zorn7, Sebastian Amigorena10, Marcelo Dias-Baruffi8,
Maurício M Rodrigues6, Seamus J Martin5, Gabriel A Rabinovich3,11 and Gustavo P Amarante-Mendes*,1,2,5
Secretory granules released by cytotoxic T lymphocytes (CTLs) are powerful weapons against intracellular microbes and tumor
cells. Despite significant progress, there is still limited information on the molecular mechanisms implicated in target-driven
degranulation, effector cell survival and composition and structure of the lytic granules. Here, using a proteomic approach we
identified a panel of putative cytotoxic granule proteins, including some already known granule constituents and novel proteins
that contribute to regulate the CTL lytic machinery. Particularly, we identified galectin-1 (Gal1), an endogenous immune regulatory
lectin, as an integral component of the secretory granule machinery and unveil the unexpected function of this lectin in regulating
CTL killing activity. Mechanistic studies revealed the ability of Gal1 to control the non-secretory lytic pathway by influencing Fas–
Fas ligand interactions. This study offers new insights on the composition of the cytotoxic granule machinery, highlighting the
dynamic cross talk between secretory and non-secretory pathways in controlling CTL lytic function.
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Immune-mediated elimination of intracellular microbes and
cancer cells is accomplished by a complex lytic process
orchestrated by CD8+ cytotoxic T lymphocytes (CTLs) and NK
cells.1–3 In response to antigen-specific recognition, biochemi-
cally defined signaling events triggered by T-cell receptor
(TCR)/CD3 engagement and crosslinking of accessory
molecules, leads to CD8 T-cell activation and differentiation.
Subsequent TCR/CD3 stimulation results in release of a
fraction of cytotoxic granules at the focal point of CTL/target
cell contact, ensuring that a single CTL can kill multiple target
cells in a specific fashion avoiding ‘off-target’ cytotoxic
effects.1–3
Among relevant molecules that serve as effectors of CTL-
mediated cytotoxicity, perforin, granzyme A and granzyme B
have been shown to have major roles in killing pathogen-
invaded as well cancer cells.4–7 Current knowledge assumes
that perforin delivers granzymes A and B, and most certainly
other granule molecules, to the cytosolic compartment of
target cells.5,7,8 In particular, granzyme B has been shown to
be an efficient initiator of the apoptotic machinery,9,10 whereas
granzyme A may account for caspase-independent events
associated with target cell death.6 However, mice deficient in
any of these molecules, either alone or in combination, are still
able to eradicate infected cells and some tumors,11 suggesting
that alternative non-overlapping or partially overlapping path-
ways may have compensatory roles.
In addition to their pro-apoptotic effects, mediators released
during the CTL attack may also function as immune regulators
controlling the activity of other immune cells in tumor, infectious or
inflammatorymicroenvironments. For example, β-chemokines, a
CD8+ antiviral factor and many cytokines, including interferon
(IFN)-γ, and tumor necrosis factor are released by activated
CTLs.12,13 In addition, regulatory mediators such as serpin PI-9
(SPI-6)14 and the lysosomal protein cathepsin B15 may
contribute to protect CTLs and NK cells from their own lytic
machinery. Because of the extreme complexity and incomplete
understanding of the molecular mechanisms that control
granule-mediated cytotoxic cell killing, identification of positive
and negative regulators associated with the purified CTL/NK
granule fraction may contribute to dissect the complexity of this
lytic machinery with the ultimate goal of manipulating this
pathway for therapeutic purposes.
Here we use a large-scale proteomic approach to identify
novel cytotoxic granule proteins. Particularly, we identified
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galectin-1 (Gal1) as one of the most abundant CTL granule
constituents and showed by confocal microscopy that Gal1
colocalizes with perforin, granzyme B, Lamp-1 and Lamp-2. In
addition, electron microscopy images clearly indicate the
presence of Gal1 at the border and inside CTL granules.
Importantly, CTLs from Lgals1−/−mice display altered capacity
to eliminate antigen-specific targets in vivo. Mechanistic
studies suggest that Gal1 can modulate cell surface Fas
ligand retention and fine tune CTL activity. This study identifies
an important new component of the cytotoxic granule
machinery and reveals a different level of regulation of CTL
lytic function.
Results
Proteomic analysis identifies major CTL granule pro-
teins. To identify novel mediators that control the CTL lytic
machinery, cytoplasmic granules of mouse H-2d-specific
cell line B6.1 were isolated as described.16 The major
bands observed in Coomassie blue-stained 1D SDS-PAGE
were sliced out of the gel and subjected to in-gel trypsin
digestion and MS/MS analysis (Figure 1a). Because of the
complexity of the samples, as each band most likely
contains several different proteins, only proteins with high
MS-Fit score, peptide coverage above 35% and a
significant number of peptide matches were selected in
this first scrutiny. Thirty-nine proteins were therefore
nominated as the most abundant proteins in our CTL
granule fraction (Table 1), including the expected perforin
and the granzymes A, B, C, E, F and G. Although the MS/
MS analysis did reveal the presence of granzymes D and H
in our samples (data not shown), both of the scores for
these granzymes did not reach our predetermined thresh-
old as to be considered among the most abundant proteins
in our preparation. The positions of all these proteins are
shown in a Coomassie blue-stained 12% SDS-PAGE gel
(Figure 1b). As a single band may be composed of one or
two major proteins or several minor proteins, we decided
not to select bands according to their abundance or
intensity as it would have been incorrect to assign relative
concentration of the selected proteins based on the MS-Fit
score or any data from our MS/MS analysis, including size
and numbers of matched peaks.
To maximize the identification of the proteins present in
our CTL granule fraction, we separated samples by 2D
SDS-PAGE, using different pI gradients (Supplementary
Figure 1). As most of the granzymes are highly basic
proteins and comprise, as far as we know, the most
abundant constituents of CTL granules, it was not surprising
to find out that a large amount of proteins were not resolved
by pI 3-6 and pI 5-8 IEF gradients. In fact, a strong label was
always detected at the very basic rim of pI 3-6 and 5-8 gels
(Supplementary Figure 1). Although we ranmany pI 7-10 2D
SDS-PAGE gels, none provided us with a good resolution of
the basic CTL granule proteins. Therefore, it was not
possible to isolate single spots of the basic proteins.
However, by consistently sampling the basic edge of both
pI 3-6 and 5-8 gels, we successfully identified some of the
granzymes (Table 2). In addition, proteomic analysis of
spots isolated from 2D gels revealed some proteins also
found in 1D gel, such as cyclophilin A, adenine phosphor-
ibosyltransferase, translationally controlled tumor protein
and heat-shock cognate 71 kDa protein (Table 2). Together,
both strategies revealed a total of 246 proteins among
which, we found proteins previously shown to be localized in
lysosomes or cytotoxic granules as well as novel putative
candidates (Supplementary Table I). Interestingly, mass
spectrometry analysis revealed the presence of Gal1, a
prototype β-galactoside-binding lectin, as a major protein of
secretory granules (Figure 1b).
Validation of mass spec data. To validate the mass
spectrometry data, we first evaluated the expression of
selected proteins in the NK cell line YT and compared to the
expression found in other cell lines of non-cytotoxic cell
origin. Western blot analysis shows that YT cells represent
the only cell line that express granzyme B (A). Remarkably,
all the other proteins were more abundant in YT cells
compared to the other cell lines, particularly TRAIL,
galectin-3 (Gal3) and DNAse γ. The expression of the
selected proteins in YT cells was confirmed by immunofluor-
escence (Supplementary Figure 2B). In particular, confocal
as well as electron microscopy revealed that Gal1 was
present inside cytotoxic granules, and colocalized with
granzyme B, perforin, Lamp-1 and Lamp-2 (Figure 2).
In vivo cytotoxic assay revealed a role for endogenous
Gal1 in killing specific CTL targets. The relative abun-
dance of Gal1 in secretory granules prompted us to evaluate
its role as a component of the cytotoxic cell machinery. We
used an in vivo CTL assay well established in our
laboratory17 based on recombinant adenovirus vaccination
to elicit specific CD8 T-lymphocyte activation and expansion.
In this cytotoxic in vivo assay, target elimination is completely
dependent on CD8+ T cells (Supplementary Figure 3).
Importantly, elimination of CTL-specific targets was impaired
in Gal1-deficient (Lgals1−/−) mice, suggesting an in vivo role
for this lectin in CTL killing (Figure 3a). Similar results were
obtained in vitro using CD8+ T cells isolated from wild-type
(WT) or Lgals1−/− mice i.p. injected 12 days earlier with
L1210 cells. Whereas CD8+ WT T cells killed around 50% of
L1210 targets in vitro, Lgals1−/− CD8+ T cells eliminated
around 10% of the same targets (Figure 3b). This altered lytic
capacity was not due to impaired degranulation as Lgals1−/−
CD8+ T lymphocytes degranulated as much as WT CD8+
T cells, as measured by CD107a externalization upon
antigenic stimulation (Figures 3c and d). Moreover, reduced
CTL killing observed in Lgals1−/− mice was not the result of a
deficiency in specific CD8+ T-lymphocyte expansion. On the
contrary, ELISPOT analysis revealed a higher frequency of
IFN-γ-producing lymph node CD8+ T cells in Lgals1−/−
compared to WT C57BL/6 mice, in response to cognate
peptide (Figures 4a and b). In addition, the numbers of
pentamer-positive CD8+ T cells were similar in WT and
Lgals1−/− mice following 7 days of immunization with Ad5.β-
gal (Figure 4c). Finally, CSFE staining of CD8+ T cells
obtaining from WTor Lgals1−/− stimulated in vitro for 72 h with
IL-2 and CD3/CD28 beads also revealed increased prolifera-
tion of Lgals1−/− cells (Figures 4d–f). Taken together, these
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data suggest that although Lgals1−/− CTLs are expanded at
higher frequency and are capable of degranulating properly
upon specific stimulation, these cells experience limitations in
killing specific targets.
CTLs lacking Gal1 show altered Fas-mediated cytotoxi-
city. In vivo CTL killing operates largely through perforin and
granzymes via the granule exocytosis pathway, although the
death receptor pathway, mainly mediated by Fas/FasL
interaction also has an important role.18,19 Using WT (Fas-
sufficient) and lpr (Fas-deficient) targets we confirmed this
observation. Whereas more than 95% of Fas-sufficient
targets were eliminated, only around 80% of FAS-deficient
lpr targets were eliminated in WT immunized mice
(Figure 5a). Importantly, immunized Lgals1−/− mice elimi-
nated equally (less efficiently) Fas-sufficient and Fas-
deficient targets (around 80–85%; Figure 5a). These results
show that the deficiency observed in Lgals1−/− CTL killing
recapitulates killing defects of Fas-deficient targets by WT
mice, suggesting that in the absence of Gal1, FAS/FASL
pathway seems to be inoperative.
Gal1 acts by retaining FasL on the CTL surface and
preventing its internalization. To explore the mechanisms
by which Gal1–glycan interactions control CTL cytotoxicity,
we performed in vitro functional assays. Because FasL
(CD95 ligand) is a 40 kDa type II membrane protein
composed of three potential N-glycosylation sites (Asn184,
Asn250 and Asn260,20,21 we hypothesized that Gal1–glycan
interactions may modulate Fas–FasL interactions by specifi-
cally retaining FasL on the surface of CTLs, thereby
prolonging interactions with Fas-positive target cells. Co-
immunoprecipitation experiments with lysates of activated
CD8+ T cells treated with recombinant Gal1 revealed specific
interactions between Gal1 and FasL (Figure 5c). Notably, flow
cytometric analysis of non-permeabilized cells demonstrated
time-dependent retention of FasL on the surface of activated
CTLs exposed to Gal1, an effect that was more pronounced
at 30 min of incubation, compared to cells treated with vehicle
control (Figures 5d and e), suggesting that Gal1 may
contribute to prolong Fas–FasL interactions at the CTL–
target interface. Thus, association of Gal1 to FasL promotes
retention of this glycoprotein on the surface of CTLs.
Figure 1 Proteomic analysis of cytotoxic cell granules. (a) Proteomic strategy; (b) 1D gel analysis of cytotoxic granules and main proteins detected by mass spectrometry
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Discussion
Exocytosis of lytic granules by cytotoxic cells is a Ca2+-
dependent phenomenon that occurs in a very coordinated
manner, initiated by the triggering of the TCR and culminating
in target-directed release of their constituents.2 To fully
understand the molecular basis of CTL killing individual
exploration of the biochemical and functional nature of purified
cytotoxic granules is mandatory. Although some of the
molecules are directly responsible for killing target cells, many
others may be associated with positive or negative immune
regulatory activities.5,13
The data presented here comprise a comprehensive list of
lytic granules components. Although our strategy is far from
revealing the totality of proteins present in the granules of
cytotoxic cells, it definitely disclosed key components of these
highly specialized organelles. In this regard, it is important to
keep in mind that MS/MS identification of complex protein
mixtures is usually biased toward the most abundant proteins,
as clearly shown in the case of proteomic analysis of the
Arabidopsis thaliana chloroplast proteome.22 One of the
reasons is that, although genomic approaches can use
protocols designed to increase the number of copies of genes
of interest, proteomic technology is still restrained by the fact
that there is no available methodology to amplify proteins in
any biological sample. Besides, not every protein in a given
sample can be properly distinguished from others by any
available methodology.
We used a combination of one- and two-dimension SDS-
PAGE to maximize our chances to identify the cytotoxic
granule components present on the cytoplasmic compartment
of CTLs. In one hand, one-dimension analysis provided us
with a picture of the most abundant proteins, based on the
molecular weight of the major bands in Coomassie blue-
stained gels. It is reasonable to speculate that individual bands
analyzed may be composed of a number of proteins with
similar molecular weight. Many of these proteins are probably
concealed by the most abundant ones and, therefore, cannot
be recognized in our scrutiny. On the other hand, although two-
dimension analysis generates isolated spots that most likely
contain a single protein, basic or acidic molecules as well as
high-molecular-weight proteins are not properly resolved in 2D
gels. In addition, technical difficulties limit isolation of any given
organelle to (the extent of 100%) purity (homogeneity).
However, despite the intrinsic obstacles to unravel the
composition of the cytotoxic granules, we have successfully
identified novel granule-associated proteins as well as others
Table 1 List of the most abundant proteins identified in 1D SDS-PAGE sample of CTL granule preparation
Protein ID Accession no. MW/pI Coverage (%) Matched peptides
Heat-shock protein HSP90-beta (TSTA) P11499 83 326/5.0 42 24
NEDD1 protein P33215 72 970/8.3 23 11
BIP/GRP78 P20029 72 423/5.1 59 38
Heat-shock cognate 71 kDa protein P08109 70 872/5.4 50 36
Perforin P10820 62 082/8.4 39 25
T-complex protein 1/TCP-1 theta/CCT-theta P42932 59 556/5.4 37 17
Zinc finger protein 94 (Zfp-94) Q9Z1D9 59 156/7.8 35 18
Pyruvate kinase, M2 isozyme P52480 57 888/7.2 50 31
Protein disulfide isomerase A3 precursor (ERp60) P27773 56 622/6.0 46 23
Alpha enolase/Enolase-1 P17182 47 141/6.4 55 27
DNAse gamma/DHP2/LS-DNAse/DNAse I-like 3 O55070 35 760/8.9 40 14
Purine nucleoside phosphorylase/Inosine phosphorylase P23492 32 277/5.8 54 18
Granzyme A precursor/TSP-1/CTLA-3 P11032 28 599/9.5 61 19
Phosphomannomutase 2 (PMM 2) Q9Z2M7 27 657/6.0 61 15
Granzyme F precursor/MCSP-3/CCP4 P08883 27 643/9.9 40 11
Granzyme E precursor/CCP3 P08884 27 494/9.7 49 13
Granzyme B/CTLA-1/CCP1 P04187 27 470/9.8 50 15
Granzyme G precursor/MCSP-1 P13366 27 381/9.6 61 13
Granzyme C/CCP2 P08882 27 311/9.3 62 17
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCH-L1) Q9R0P9 24 838/5.1 40 10
Ras-related Rab-17 P35292 23 640/5.4 39 7
Ras-related protein Rab-2A P53994 23 548/6.1 57 9
PPIase precursor/Rotamase/Cyclophilin B P24369 22 713/9.5 56 15
Peroxiredoxin 1 (thioredoxin peroxidase 2) P35700 22 177/8.3 41 9
60S ribosomal protein L9 P51410 21 882/10 58 12
Ferritin light chain 1 P29391 20 803/5.7 46 7
Adenine phosphoribosyltransferase/APRT P08030 19 763/6.3 58 9
Translationally controlled tumor protein (TCTP) P14701 19 462/4.8 42 12
40S ribosomal protein S10 P09900 18 916/10.2 70 14
Cofilin P18760 18 560/8.2 69 12
PPIase/Rotamase/Cyclophilin A P17742 17 972/7.7 45 12
40S ribosomal protein S16 P14131 16 356/10.2 68 11
Superoxide dismutase [Cu-Zn] P08228 15 943/6.0 54 9
Myosin light chain alkali (MLC3nm) Q60605 15 731/4.8 62 8
Cystatin C P21460 15 531/9.2 53 6
Profilin I P10924 14 957/8.5 46 8
Galectin-1 P10812 14 866/5.3 62 10
Histone H2A P22752 14 182/10.9 63 7
Histone H2B P10854 13 936/10.3 65 18
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already known to be present in either CTL or NK granules.
Importantly, they were all found to be associated with the
organelle fraction enriched for many of the proteins known to
be present in the lytic granules. Moreover, all received a high-
confidence MS-Fit score and displayed significant peptide
coverage.
Two major strategies have been used to assign proteins to
specific subcellular compartments. The first uses confocal
microscopy approaches to reveal colocalization with well-
established markers. The sensitivity of this method may not
allow proper labeling of proteins present at low concentration.
Furthermore, if the protein is also present in any other
compartment, the specific signal may be disguised. That
might well be the case of a fraction of the proteins identified in
this study. The second approach is based on the ectopic
expression of constructs designed to contain molecular tags.
Although this strategy greatly increases the detection limit for
low abundance proteins, it is possible that proteins expressed
in such way may not be properly folded and/or transported
within the cell and, consequently, ended up in different
compartment than the endogenous counterparts. Neverthe-
less, it is important to emphasize that the novel proteins
presented in this study may not have an exclusive cytotoxic
granule localization, as is clearly the case of Gal1, an immune
regulatory lectin widely distributed inmultiple cells, tissues and
subcellular compartments.
Gal1 is a prototype member of a family of endogenous
lectins, which functions intracellularly by interacting with
intracellular signaling components or extracellularly by recog-
nizing N-acetyllactosamine (Galβ1–4-GlcNAc; LacNAc) resi-
dues on a myriad of cell surface glycosylated receptors,
including CD45, CD43 and CD7.23 This lectin has been
implicated in the regulation of innate and adaptive immune
responses through multiple mechanisms. In the periphery,
Gal1 selectively dampens Th1 and Th17 responses,24,25
induces IL-10 secretion,26,27 inhibits T-cell trafficking28 and
decreases antigen-presenting capacity by macrophages.24
Furthermore, exposure to Gal1 promotes the differentiation of
IL-27-producing tolerogenic dendritic cells29 and favors the
expansion of inducible T regulatory cells.30 Within the CD8+
T-cell compartment, Gal1 is induced in activated CD8 T cells
and functions as an autocrine negative regulator of CD8+ T-cell
binding, signal transduction and burst size.31 Gal1 deficiency
results in increased frequency of CD8+ T cells and CD8-
mediated tumor rejection in several tumor models.32–34 Here
we defined a novel role for Gal1 as a component of CTL lytic
granules that contributes to CTL effector function. Given the
complexity of CTL biology, the overall positive or negative
effects of this lectin in CTL function might depend on the
pathophysiologic context and the relative contribution of this
lectin to different stages of CTL lifespan, including activation,
expansion, granule release and contraction. In this regard, we
found here that Gal1 negatively controls proliferation of CD8+
Table 2 List of proteins identified by 2D electrophoresis of CTL granule preparation
Spot Protein ID Accession no MW/pI Coverage (%) Matched peptides
1 β-spectrin/fodrin Q62261 27 4425/5.7 27 65
2 aBIP/GRP78 P20029 72 423/5.1 54 26
3 aHeat-shock cognate 71 kDa protein P08109 70 872/5.4 36 20
4 75 kDa glucose regulated protein (GRP 75)/Mortalin P38647 73 529/5.9 19 8
5 Vimentin P20152 53 688/5.1 21 12
6 Calreticulin/calregulin/ERP60 NP_031617 48 136/4.33 53 24
7 Calreticulin/calregulin/ERP60 NP_031617 48 136/4.33 54 23
8 aDisulfide isomerase ER-60 P27773 56 622/6.0 42 20
9 Angiopoietin-related protein 2 precursor Q9R045 57 119/7.3 20 7
10 aAlpha enolase/Enolase-1 P17182 47 453/6.4 76 34
11 aAlpha enolase/Enolase-1 P17182 47 453/6.4 45 18
12 Cathepsin D precursor P18242 44 954/6.7 34 13
13 Cathepsin D precursor P18242 44 954/6.7 34 12
14 β-actin NP_001092 42 052/5.29 42 12
15 Aldose reductase P45376 35 733/6.7 24 7
16 NUDIX NP_705789 35 623/9.15 38 13
17 aGranzyme E P08884 27 494/9.7 26 5
18 aGranzyme A/CTLA-3/TSP-1 P11032 28 599/9.5 41 9
19 aGranzyme A/CTLA-3/TSP-1 P11032 28 599/9.5 57 17
20 aGranzyme A/CTLA-3/TSP-1 P11032 28 599/9.5 46 10
21 Chloride intracellular channel protein 1/NCC27/p64 CLCP Q9Z1Q5 27 013/5.1 44 9
22 Chloride intracellular channel protein 1/NCC27/p64 CLCP Q9Z1Q5 27 013/5.1 39 9
23 Proteasome subunit alpha type 1/Macropain subunit C2 Q9R1P4 29 547/6.0 34 9
24 Ubiquitin carboxyl-terminal hydrolase isozyme L3 (UCH-L3) Q9JKB1 26 152/5.0 43 7
25 Phosphoglycerate mutase 1/PGAM-B Q9DBJ1 28 832/6.7 59 13
26 aGranzyme C/CCP2 P08882 27 311/9.3 75 25
27 Triosephosphate isomerase/TIM P17751 26 713/6.9 48 13
28 Triosephosphate isomerase/TIM P17751 26 713/6.9 40 9
29 aTranslationally controlled tumor protein (TCTP) P14701 19 462/4.8 37 8
30 aTranslationally controlled tumor protein (TCTP) P14701 19 462/4.8 44 12
31 aAdenine phosphoribosyltransferase/APRT P08030 19 763/6.3 58 8
32 aGranzyme B/CTLA-1/CCP1 P04187 27 470/9.8 30 7
33 Nucleoside diphosphate kinase B (NDK B)/ NM23-M2 Q01768 17 363/7.0 68 9
34 aPPIase/Rotamase/Cyclophilin A P17742 17 972/7.7 50 9
aAlso identified by 1D electrophoresis.
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T cells, whereas amplifies FasL-mediated killing activity.
Moreover, our findings show that Gal1 may retain FasL on
the surface of CTLs, suggesting that this lectin could delay
FasL endocytosis and prolong interactions with Fas-positive
target cells. Interestingly, this lectin has been shown to
increase cell surface residency and prevent endocytosis of
various glycosylated receptors, including the CD45 phospha-
tase in microglia cells23 and vascular endothelial growth factor
receptor 2 on the surface of endothelial cells.32 Thus, lectin–
glycan interactions can amplify or interrupt cell–cell commu-
nication by modulating endocytosis, trafficking and signaling
of canonical receptors. Importantly, as blockade of Gal1 in
most cancer models results in CD8+ T-cell-mediated tumor
rejection,32,33 it seems apparent that under conditions in which
Gal1 secretion is substantially increased (i.e., tumor or
inflammatory microenvironments), contraction of the CD8+
T-cell compartment and inhibition of CTL function will certainly
prevail.
In conclusion, using an interdisciplinary approach ranging
from proteomics search to biochemical and functional assays,
we identified a novel role of Gal1 as an integral component of
the CTL lytic machinery. Moreover, our proteomics strategy
sets the stage for further studies to unravel the function of the
newly identified proteins in cytotoxic cell degranulation, killing
and immunomodulation.
Materials and Methods
Mice and ethics statement. Six- to eight-week-old WT, CD8−/− or Gal1-
deficient (Lgals1−/−) C57BL/6 mice (all males) were housed at our animal facility at
the Institute of Biomedical Sciences, University of Sao Paulo (ICB-USP). This study
was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the Brazilian National Council of Animal
Experimentation (http://www.cobea.org.br/). The protocols were approved by the
Animal Ethics Committee of the ICB-USP.
Cell culture. The L1210 and the NK line YT were maintained in RPMI-1640
supplemented with 10% FCS, 25 mM HEPES, 2 mM L-glutamine, 100 U/ml
penicillin and 100 μg/ml streptomycin.
Antibodies and reagents. MytoTracker and LysoTracker were obtained from
Molecular Probes (Eugene, OR, USA). Antibodies were from different sources. Anti-
perforin (clone δG9), anti-TRAIL (clone III6F) and anti-granzyme A mAbs (clone
Figure 2 Confocal and electron microscopy of YT cells. (a) Confocal microscopy showing colocalization of Gal1 with granzyme B, perforin, Lamp-1 and Lamp-2; (b) electron
microscopy showing Gal1 localization inside cytotoxic granules
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GA6) were purchased from Alexis Biochemicals/Enzo Life Sciences, Inc.
(Farmingdale, NY, USA). Anti-Gal1 and anti-galectin-3 mAbs were obtained from
R&D Systems, Inc. (Minneapolis, MN, USA). Anti-DNase γ mAb (Ab-1) was
purchased from Oncogene Research Products (La Jolla, CA, USA) and anti-
granzyme B pAb (ab4059) was from Abcam (Cambridge, UK). Anti-perforin mAb
(clone CB5.4) was acquired from Apotech Co. (Epalinges, Switzerland). Anti-cofilin
and anti-profilin pAbs were purchased from Cytoskeleton, Inc. (Denver, CO, USA).
Secondary antibodies coupled with Alexa Red 546 or Alexa 488 were acquired from
Invitrogen (Carlsbad, CA, EUA). CTL granule preparation was kindly provided by Dr.
Jürg Tschopp and corresponds to formulation described in ref. 16.
Separation of granule proteins by electrophoresis. CTL granule
proteins were precipitated in 13% TCA. After 1 h incubation at 4 °C, samples were
centrifuged at 15 000 × g for 15 min at 4 °C and pellets were washed twice in 1 ml
of cold acetone. For 1D analysis, the dried pellets were resuspended in SDS-PAGE
loading buffer (100 mM DTT, 2% SDS, 10% glycerol, 0,1% bromophenol blue and
50 mM Tris-Cl, pH 6.8) and separated by SDS-PAGE according to Laemmli.35 For
2D analysis, pellets were dissolved in IEF sample buffer (8 M urea, 4% CHAPS,
0.05% SDS, 100 mM DTT, 0.5 % Bio-Lyte ampholyte, plus a trace of bromophenol
blue) and initially used to rehydrated IPG strips overnight. First dimension IEF was
carried out on a Protean IEF Cell (Bio-Rad, Hercules, CA, USA) for a total of
55 000 Vh and second dimension on a Protean II xi Cell (Bio-Rad). After protein
separation, gels were stained with either Coomassie brilliant blue or silver nitrate as
described.36
Mass spectrometry analysis. Spots were excised from silver-stained 2D
gels, washed once in oxidation buffer (15 mM K3Fe(CN)6 and 50 mM Na2S2O3) and
then successively in 50% methanol/40% acetic acid. After equilibration in
NH4HCO3, gel pieces were dehydrated in 100% acetonitrile and desiccated
completely in Speed-vac at low heat setting. In-gel tryptic digestion was performed
overnight at 37 °C in 12 μl of 10 μg/ml trypsin in 25 mM NH4HCO3/0.1%
n-octylglucoside. Peptide mass fingerprinting was performed by MALDI-MS in a
Voyager-DE PRO Biospectrometry Workstation (Applied Biosystems, Foster City,
CA, USA). Tryptic fragments were spotted onto the MALDI sample probe, in the
presence of α-cyano-4-hydroxy-trans-cinnamic acid (Sigma, St Louis, MO, USA).
Monoisotopic peptide masses were assigned and used to search the Swiss-Prot
Figure 3 Altered cytotoxic activity of Lgals1−/− CD8+ T cells. (a) In vivo antigen-specific target elimination by WTor Lgals1−/− C57BL/6 mice immunized or not with 2 × 108
PFU of Ad5β-gal 8 days before. (b) In vitro killing of L1210 targets by CD8+ T cells obtained from the peritoneal cavity of WTor Lgals1−/− C57BL/6 mice injected 12 days before
with L1210 cells. (c and d) WT or Lgals1−/−CD8+ T-cell degranulation upon antigen-specific stimulation, as measured by Lamp-1 (CD107a) externalization
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database using the MS-Fit program (University of California, San Francisco—http:/
prospector.ucsf.edu/).
Western blot analysis. Protein samples were resolved under reducing
conditions for 2 h at 80 V in SDS-polyacrylamide gels, as previously described.37
Briefly, cells were collected, washed once in ice-cold PBS, lysed directly in SDS-
PAGE loading buffer and boiled for 5 min before SDS-PAGE. Separated proteins
were blotted onto nitrocellulose or PVDF membranes at 150 mA overnight. Blots
were blocked in TBST (10 mM Tris-HCl, pH 7.4, 150 mM NaCl and 0.05% Tween)
containing 0.1% sodium azide and 5% nonfat dried milk and then probed for 2 h
with an appropriate dilution of the primary antibody. Reactions were detected with
suitable secondary antibody conjugated to horseradish peroxidase (Amersham,
Arlington, IL, USA) using enhanced chemiluminescence (Pierce, Rockford,
IL, USA).
Immunofluorescence and confocal microscopy. Colocalization of
Gal1 and cytotoxic granule proteins were performed as described.38 In brief, cells
were collected, washed with cold PBS, placed on poly-L-lysine (Sigma)-covered
glass slides and incubated for 30 min at 37 °C. Supernatants were removed and
cells fixed in 2% paraformaldehyde for another 30 min at 4 °C before subjected to
permeabilization with PBS containing 0.1% Triton X-100 and 1% BSA. Cells were
washed again and labeled with desired antibodies for 30 min at 37 °C before
analyzed in a Zeiss LSM 510 microscope (Carl Zeiss Jena GmbH, Jena, Germany)
using C-Apochromat × 40 and × 60 (zoom of × 120) objectives. The fluorophores
used in all experiments were Alexa Red 546 (red image) or Alexa 488 (green
Image). Pinhole size was 95.6 μm. Images are from a single plane.
Immunoelectron microscopy. Cells were fixed for 24 h at 4 °C in 0.1 M
sodium cacodylate buffer (pH 7.4) containing 1% glutaraldehyde and 4%
paraformaldehyde, followed by a postfixation with 1% (w/v) osmium tetroxide in
the cacodylate buffer for 2 h at 4 °C. The samples were than washed several times
in graded series of ethanol and embedded in LR White Resin Grade Acrylic Resin
(London Resin Company, Ltd, Aldermaston, UK) at 37 °C 72 h. Ultrathin sections
(50 nm thick) were obtained with a MT-2 Sorvall ultramicrotome and collected onto
palloidium-coated nickel grid (Electron Microscope Sciences, Hatfield, PA, USA) and
then submitted to single immunogold procedure. Briefly, grades carrying ultrathin
sections were hydrated with distilled water, followed by rinsing with TBS/glycine
(0,02 M, pH 7.2) to avoid crosslinking with the fixative. Nonspecific sites were
blocked by incubating the section for 30 min at room temperature (RT) with TBS (pH
7.2) containing 3% BSA, 0.05% NaN3 and 0.1% Tween 20, diluted 1 : 1 in normal
goat serum. Sections were then incubated overnight at 4 °C with anti-Gal1 antibody
(Invitrogen). After being rinsed with washing buffer (TBS, pH 7.2, containing 0.1%
BSA, 0.05% NaN3 and 0.1% Tween 20), sections were incubated for 2h with donkey
anti-mouse IgG coupled with 18 nm gold particles (Jackson ImmunoResearch
Laboratories, Inc., West Grove, PA, USA) for 2h at RTand washed in washing buffer.
Finally, the samples were fixed with 2.5% glutaraldehyde in 0.1 M sodium
cacodylate buffer (pH 7.4) for 10 min (RT). Subsequently, the grids were washed in
distillated water, stained with uranyl acetate and lead citrate and examined with a
JEOL 100 CX II 100KW transmission electron microscope (Jeol, Tokyo, Japan).
ELISPOT and in vivo cytotoxic assay. The frequency of antigen-specific
CD8+ T cells was evaluated by ELISPOT analysis of IFN-γ-secreting cells39 and
their effector function was measured by the in vivo cytotoxic assay.17 Concisely,
mice were immunized intramuscularly (i.m.) in each tibialis anterior muscle with
50 μl containing 1 × 108 PFU of human type 5 replication-deficient adenoviruses
expressing β-galactosidase (Adβ-gal). Target cells were obtained from syngeneic
WT or Fas-deficient lpr C57Bl/6 mice and labeled with carboxyfluorescein diacetate
succinimidyl diester (CFSE; Molecular Probes) at final concentration of 10 μM
(CFSEhigh) or 1 μM (CFSElow). The CFSEhigh population was pulsed for 40 min at
37 °C with 1 μM of the H-2Kb-restricted ICPMYARV peptide, a representative β-gal
epitope (β-Gal 497–504, Genscript). Seven days after immunization, mice were
inoculated by the retro-orbital route with 2 × 107 CFSElow and 2 × 10
7 CFSEhigh cells
in a total volume of 200 μl of RPMI-1640 without serum. After 20 h, mice were killed
according to procedures approved by the Animal Ethic Committee of our Institute
and their spleens removed and processed for ELISPOT and flow cytometry (BD
FACSCanto II; BD Biosciences, San Jose, CA, USA). The percentage of specific
target lysis was determined using the following formula:
1%CFSEhighinfected=%CFSElowinfected
%CFSEhighnaive=%CFSElownaive
´100%
In vitro proliferation and activation profile assay. Lymphocytes were
obtained from lymph nodes from WTand Lgals1−/− C57BL/6 mice and CD8+ T cells
Figure 4 Lgals1−/− CD8+ T cells displayed enhanced in vitro and in vivo proliferating capacity compared to WT cells. (a and b) ELISPOTanalysis of IFN-γ-producing lymph
node cells obtained from WTor Lgals1−/− C57Bl/6 mice immunized or not with Ad5.βgal for 7 days and in vitro stimulated with cognate peptide ICP. (c) Antigen-specific CD8+
T cells obtained from spleens of WTor Lgals1−/− C57Bl/6 mice immunized or not with Ad5.βgal for 7 days, assessed as pentamer-positive events. (d–f) In vitro proliferation of WT
or Lgals1−/− CD8 T cells stimulated for 72 h with 40 U/ml IL-2 and 10 μl/ml of CD3/CD28 beads. (d) Histogram represents the peaks of CFSE dilution of dividing cell populations.
Bars represent (e) average stage of division and (f) percentage of cells in different stages of divisions in response to stimulation by IL-2 and anti-CD3/anti-CD28 mAb as
determined from the CFSE dilution profile in d
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were enriched using CD8a+ T cells Isolation Kit II (Miltenyi Biotec, San Diego, CA,
USA) and magnetic cell separation (AutoMACS). The purity of CD8+ T cells was
485%. CD8a cells were labeled with 5 mM CFSE and stimulated in 12-well plates
for 3 or 6 days with or without 40 U/ml IL-2 and 10 μl/ml, and CD3/CD28 beads (Life
Technologies AS, Oslo, Norway). Flow cytometry was performed in a BD
FACSVerse (BD Biosciences) and analyzed using FlowJo software (Ashland, OR,
USA). The average stage of cell division was calculated based on CFSE histograms
gated in the CD3+ CD8+ T cells.
Preparation of recombinant Gal1. Purification of recombinant Gal1 was
accomplished as outlined previously.24 Potential LPS contamination was carefully
removed by Detoxi-GelTM (Pierce) and tested using a Gel Clot Limulus Test
(o0.5 IU/mg; Cape Cod).
Co-immunoprecipitation of FasL and Gal1 and flow cytometry.
CTLs were isolated from normal spleen (Mouse CD8 Cells Kit, Invitrogen cat.
number 11417D) and pre-incubated with or without recombinant Gal1 (25 μg/ml) for
15 min as described.23 For co-immunoprecipitation, 500 μg cell lysates were
incubated with 2 μg anti-FasL or isotype control antibodies (FasL sc-956; isotype
control sc-2027; Santa Cruz Biotechnology, Dallas, TX, USA). The immunocom-
plexes were captured with Protein G PLUS-Agarose (Santa Cruz Biotechnology)
and processed for immunoblotting. Cell surface expression of FasL was analyzed in
non-permeabilized cells (2 × 105 cells) by flow cytometry. Briefly, purified CD8+
T cells were incubated or not with anti-CD3/anti-CD28 mAb (1 μg/μl clone 145-
2C11; 1 μg/μl clone 37.51) for 18 h and then stimulated with PBS or Gal1 for the
indicated time periods. Cells were analyzed for FasL expression using the anti-FasL
mAb (clone MFL3; eBioscience, San Diego, CA, USA). Nonspecific binding
determined with isotype-matched control antibodies is shown. Cells were then
analyzed on a FACSAria II flow cytometry (BD Biosciences).
Degranulation assay (Lamp-1/CD107a externalization). For
CD107a staining, splenocytes collected from WT or Lgals1−/− C57BL/6 mice were
treated with ACK buffer. Staining was performed after in vitro culture of splenocytes
in the presence or absence of the peptides indicated in each figure. Cells were
washed three times in plain RPMI-1640 medium and resuspended in same medium
supplemented with 10 mM Hepes, 0.2% sodium bicarbonate, 59 mg/l of penicillin,
133 mg/l of streptomycin, 10% Hyclone fetal bovine serum, 2 mM L-glutamine,
1 mM sodium pyruvate and 55 μM 2-mercaptoethanol. The viability of the cells was
evaluated using 0.2% trypan blue exclusion dye to discriminate between live and
dead cells. Cell concentration was adjusted to 5 × 106 cells/ml. In half of the
cultures, a final concentration of 10 μM of the VNHRFTLV peptide was added. The
cells were cultivated in V-bottom 96-well plates (Corning) in a final volume of 200 μl
in duplicate, at 37 °C in a humid environment containing 5% CO2. After 8 h
incubation, cells were stained for surface markers with CD3 FITC (GK1.5) and CD8
PerCP (53–6.7) and anti-CD107a (1D4B) antibodies on ice for 20 min. At least
8 × 105 cells were acquired on a BD FACSCanto II flow cytometer and then
analyzed with FlowJo.
Statistical analysis. Groups were compared using one way ANOVA followed
by Tukey’s HSD test (http://faculty.vassar.edu/lowry/VassarStats.html). The differ-
ences were considered significant when the P-value was o0.05.
Figure 5 Lgals1−/− CD8+ T cells are as efficient as WT CD8+ T cells at killing peptide-pulsed FAS-deficient target cells. (a) In vivo cytotoxic assay comparing the efficiency of
WT or Lgals1−/− mice to eliminate Fas-sufficient or -deficient target cells. (b) Colocalization of FasL and Gal1 in YT cells by confocal microscopy. (c) Co-immunoprecipitation
followed by immunoblotting of Gal1 and FasL expression in lysates from CD8 purified cells incubated with anti-CD3 and anti-CD28 mAb for 18 h and further stimulated (+) or not
(− ) with recombinant Gal1 (rGal1). Input, whole cell lysate; IP, immunoprecipitation. Ponceau S staining of all the proteins ran is shown (upper panel). (d and e) Flow cytometry
analysis of FasL expression in non-permeabilized, purified CD8+ T cells incubated or not with anti-CD3/anti-CD28 mAb for 18 h and then stimulated with PBS or rGal1 for the
indicated time periods. Nonspecific binding determined with isotype-matched control antibodies is shown. (d) Curves of rMFI (median fluorescence intensity of specific marker
signal–median fluorescence intensity of unspecific signal) for each time period analyzed. (e) Retention of FasL on the surface of purified CD8+ T cells. Numbers show the
percentage of positive cells
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